Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com 5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines